Paion AG
F:PA8
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| DE |
|
Paion AG
XETRA:PA8
|
1.8m EUR |
-9%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
115%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.5B USD |
88%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
154B USD |
99%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
149.3B USD |
33%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-877%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
94.7B USD |
23%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
126.3B AUD |
15%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
59.7B USD |
15%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
56.1B USD |
-258%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-28%
|
Paion AG
Glance View
PAION AG operates as a pharmaceutical company. The company is headquartered in Aachen, Nordrhein-Westfalen and currently employs 56 full-time employees. The company went IPO on 2012-03-29. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on Paion AG's most recent financial statements, the company has ROE of -8.8%.
You don't have any saved screeners yet